[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611588":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":115,"collaborators":25,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":119,"sex":125,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":25,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":91,"whyStopped":25,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Fundacion Dexeus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide","EXPERIMENTAL","Semaglutide 0.25-1.0 mg for 12 weeks prior to ovarian stimulation",[13],"Drug: Semaglutide",{"label":15,"type":16,"description":17,"interventionNames":18},"No pre-treatment","ACTIVE_COMPARATOR","No pre-treatment prior to ovarian stimulation Pre-treatment",[19],"Other: No pre-treatment",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Participants in this group will receive semaglutide for 12 weeks before ovarian stimulation (0.25 mg\u002Fweek in weeks 1-4, 0.5 mg\u002Fweek in weeks 5-8, and 1 mg\u002Fweek in weeks 9-12). After pre-treatment, controlled ovarian stimulation will be initiated with 225-300 IU\u002Fday of rFSH, GnRH antagonist (0.25 mg\u002Fday) starting when follicles reach ≥14 mm, and ovulation triggered with triptorelin 0.2 mg when 2-3 follicles reach ≥18 mm. Oocyte retrieval will occur 34-36 hours later, followed by IVF\u002FICSI. Embryos will be cultured to blastocyst stage and cryopreserved. Embryo transfer will occur after an 8-week washout from semaglutide.",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants in this group will undergo standard ovarian stimulation without semaglutide pre-treatment. Stimulation will begin with 225-300 IU\u002Fday of rFSH, GnRH antagonist (0.25 mg\u002Fday) starting when follicles reach ≥14 mm, and ovulation triggered with triptorelin 0.2 mg when 2-3 follicles reach ≥18 mm. Oocyte retrieval will be performed 34-36 hours later, followed by IVF\u002FICSI. Embryos will be cultured to the blastocyst stage and cryopreserved. Embryo transfer will follow standard clinical practice.",[15],[30],{"name":31,"affiliation":32,"role":33},"Nikolaos P Polyzos, MD, PhD","Dexeus Fertility","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","0034932274700","nikpol@dexeus.com",{"name":40,"role":36,"phone":37,"phoneExt":41,"email":42},"Ignacio Rodríguez, MSc","22029","nacrod@dexeus.com",[44,62,74,89,103],{"facility":45,"status":46,"city":47,"state":48,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Dexeus Mujer Sabadell","NOT_YET_RECRUITING","Sabadell","Barcelona","Spain","ES",{"type":52,"coordinates":53},"Point",[54,55],2.10942,41.54329,{"lat":55,"lon":54},[58,61],{"name":59,"role":36,"phone":37,"phoneExt":25,"email":60},"Ainhoa Coco, MD","aincoc@dexeus.com",{"name":59,"role":33,"phone":25,"phoneExt":25,"email":25},{"facility":63,"status":46,"city":64,"state":48,"zip":65,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Dexeus Mujer Sant Cugat","Sant Cugat del Vallès","08195",{"type":52,"coordinates":67},[68,69],2.08611,41.47063,{"lat":69,"lon":68},[72,73],{"name":59,"role":36,"phone":37,"phoneExt":25,"email":60},{"name":59,"role":33,"phone":25,"phoneExt":25,"email":25},{"facility":75,"status":46,"city":76,"state":77,"zip":78,"country":49,"countryCode":50,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Dexeus Mujer Reus","Reus","Tarragona","43202",{"type":52,"coordinates":80},[81,82],1.10687,41.15612,{"lat":82,"lon":81},[85,88],{"name":86,"role":36,"phone":25,"phoneExt":25,"email":87},"Josep Gonzalo, MD","JOSGON@dexeus.com",{"name":86,"role":33,"phone":25,"phoneExt":25,"email":25},{"facility":90,"status":91,"city":48,"state":25,"zip":92,"country":49,"countryCode":50,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus","RECRUITING","08028",{"type":52,"coordinates":94},[95,96],2.15899,41.38879,{"lat":96,"lon":95},[99,100],{"name":40,"role":36,"phone":37,"phoneExt":41,"email":42},{"name":101,"role":102,"phone":25,"phoneExt":25,"email":25},"Valeria Donno, MD","SUB_INVESTIGATOR",{"facility":104,"status":46,"city":77,"state":25,"zip":105,"country":49,"countryCode":50,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Dexeus Mujer Tarragona","43206",{"type":52,"coordinates":107},[108,109],1.24544,41.11905,{"lat":109,"lon":108},[112,114],{"name":86,"role":36,"phone":25,"phoneExt":25,"email":113},"josgon@dexeus.com",{"name":86,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":116,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100611588","phase-4-effect-of-semaglutide-on-embryo-quality-in-overweight-and-obese-patients-undergoing-in-vitro-fertilization-100611588",false,"NCT07242534","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial","SEQ","Inclusion Criteria:\n\n* ≤ 38 years\n* AMH \\>= 1 ng\u002FmL or AFC \\>= 6\n* Body mass index (BMI) between 27 kg\u002Fm2 and 40 kg\u002Fm2\n* Scheduled for IVF with freeze-all strategy\n\nExclusion Criteria:\n\n* Severe male factor (sperm concentration \\\u003C5M\u002FmL)\n* Type 2 diabetes mellitus\n* Prior use of GLP-1 Ras within the past year\n* Uncontrolled thyroid disorders\n* Contraindications to IVF or semaglutide treatment\n* Patients with chronic inflammatory diseases\n* Family history of hereditary or chromosomal diseases\n* Use of glucocorticoids or immunosuppressants\n* PGT-A\n* Use of medications affecting metabolism or inflammation","FEMALE","18 Years","38 Years",{"count":129,"type":130},62,"ESTIMATED","INTERVENTIONAL",[133],"PHASE4","This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.",[136,137],"Infertility","Obesity",[137,139,140,141,142],"Overweight","GLP-1 receptor agonist","IVF","ART","2026-01-19",{"date":145,"type":146},"2026-01-21","ACTUAL",{"date":143,"type":146},{"date":149,"type":130},"2027-05",{"name":5,"class":6},5]